Placebo/Vehicle

OTHER4 trials

Sponsors

Alios Biopharma Inc., Pulmocide Ltd, EyePoint Pharmaceuticals, Inc.

Conditions

CataractInfluenzaRespiratory Syncytial Virus Infections

Phase 1

A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study

CompletedNCT02588521

Alios Biopharma Inc.Influenza

Start: 2015-08-31End: 2017-08-14Updated: 2017-10-11

A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study

CompletedNCT03382431

Pulmocide LtdRespiratory Syncytial Virus Infections

Start: 2017-11-14End: 2018-05-09Updated: 2018-05-16

Phase 3

A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)

WithdrawnNCT05550363

EyePoint Pharmaceuticals, Inc.Cataract

Start: 2022-09-30End: 2023-09-30Updated: 2024-04-03

A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery

WithdrawnNCT05550350

EyePoint Pharmaceuticals, Inc.Cataract

Start: 2022-09-30End: 2023-09-30Updated: 2025-08-11

Related Papers

Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study

The Journal of Infectious Diseases2020-11-1344 citations

Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study

The Journal of Infectious Diseases2018-07-0723 citations